Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BIRC2 | Q13490 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | MME | P08473 | 2/20 | 0.38 |
| ▸ | NOS3 | P29474 | 5/20 | 0.36 |
| ▸ | NOS1 | P29475 | 5/20 | 0.36 |
| ▸ | NOS2 | P35228 | 5/20 | 0.36 |
| ▸ | TAS1R3 | Q7RTX0 | 4/20 | 0.36 |
| ▸ | TAS1R1 | Q7RTX1 | 4/20 | 0.36 |
| ▸ | ACE | P12821 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28291134 | 0.85 | CA1 (0.42) | CA1CA2NOS3NOS1NOS2 | |
| SCHEMBL16487289 | 0.84 | MME (0.43) | BIRC2MMETAS1R3TAS1R1SMN1; SMN2 | |
| SCHEMBL13103827 | 0.81 | CA1 (0.39) | CA1CA2MMENOS3NOS1 | |
| SCHEMBL12868880 | 0.80 | SMN1; SMN2 (0.44) | BIRC2MMETAS1R3TAS1R1SMN1; SMN2 | |
| SCHEMBL5514853 | 0.80 | SMN1; SMN2 (0.44) | BIRC2MMETAS1R3TAS1R1SMN1; SMN2 | |
| SCHEMBL9911582 | 0.80 | SMN1; SMN2 (0.44) | BIRC2MMETAS1R3TAS1R1SMN1; SMN2 | |
| SCHEMBL13880232 | 0.79 | CA1 (0.47) | BIRC2CA1CA2NOS3NOS1 | |
| SCHEMBL28312044 | 0.79 | MGAM (0.39) | BIRC2MMETAS1R3TAS1R1SMN1; SMN2 | |
| SCHEMBL9203451 | 0.78 | CA1 (0.37) | BIRC2CA1CA2NOS3NOS1 | |
| SCHEMBL6947237 | 0.77 | MME (0.39) | BIRC2MMETAS1R3TAS1R1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120322761-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322761-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | BIRC2 2760/4885CA1 4507/4885CA2 3976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.